| Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study … DO Persky, JM Unger, CM Spier, B Stea, M LeBlanc, MJ McCarty, ... Journal of clinical oncology 26 (14), 2258-2263, 2008 | 361 | 2008 |
| Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B-and T-cell non-Hodgkin lymphomas JW Friedberg, D Mahadevan, E Cebula, D Persky, I Lossos, AB Agarwal, ... Journal of clinical oncology 32 (1), 44-50, 2014 | 258 | 2014 |
| Interactions of elongation factor 1α with F-actin and β-actin mRNA: implications for anchoring mRNA in cell protrusions G Liu, WM Grant, D Persky, VM Latham Jr, RH Singer, J Condeelis Molecular biology of the cell 13 (2), 579-592, 2002 | 218 | 2002 |
| Blocking “don't eat me” signal of CD47-SIRPα in hematological malignancies, an in-depth review A Russ, AB Hua, WR Montfort, B Rahman, IB Riaz, MU Khalid, JS Carew, ... Blood reviews 32 (6), 480-489, 2018 | 178 | 2018 |
| Outcomes of patients with double-hit lymphoma who achieve first complete remission DJ Landsburg, MK Falkiewicz, J Maly, KA Blum, C Howlett, T Feldman, ... Journal of Clinical Oncology 35 (20), 2260-2267, 2017 | 169 | 2017 |
| Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP LM Rimsza, ML LeBlanc, JM Unger, TP Miller, TM Grogan, DO Persky, ... Blood, The Journal of the American Society of Hematology 112 (8), 3425-3433, 2008 | 166 | 2008 |
| Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma CJ Stasik, H Nitta, W Zhang, CH Mosher, JR Cook, RR Tubbs, JM Unger, ... Haematologica 95 (4), 597, 2010 | 125 | 2010 |
| Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic … LF Porrata, MR Litzow, DJ Inwards, DA Gastineau, SB Moore, AA Pineda, ... Bone Marrow Transplantation 33 (3), 291-298, 2004 | 120 | 2004 |
| A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108 AT Stopeck, JM Unger, LM Rimsza, WT Bellamy, M Iannone, DO Persky, ... Leukemia & lymphoma 50 (5), 728-735, 2009 | 119 | 2009 |
| The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple … LF Porrata, MA Gertz, SM Geyer, MR Litzow, DA Gastineau, SB Moore, ... Leukemia 18 (6), 1085-1092, 2004 | 115 | 2004 |
| Continued risk of relapse independent of treatment modality in limited-stage diffuse large B-cell lymphoma: final and long-term analysis of Southwest Oncology Group Study S8736 DM Stephens, H Li, ML LeBlanc, SD Puvvada, D Persky, JW Friedberg, ... Journal of Clinical Oncology 34 (25), 2997-3004, 2016 | 112 | 2016 |
| Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL 2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory … AW Roberts, RH Advani, BS Kahl, D Persky, JW Sweetenham, DA Carney, ... British journal of haematology 170 (5), 669-678, 2015 | 112 | 2015 |
| Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T‐cell non‐Hodgkin lymphoma: Southwest Oncology Group Study S0350 D Mahadevan, JM Unger, CM Spier, DO Persky, F Young, M LeBlanc, ... Cancer 119 (2), 371-379, 2013 | 110 | 2013 |
| Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1 L Li, P Pongtornpipat, T Tiutan, SL Kendrick, S Park, DO Persky, ... Leukemia 29 (8), 1702-1712, 2015 | 108 | 2015 |
| Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review F Anwer, AA Shaukat, U Zahid, M Husnain, A McBride, D Persky, M Lim, ... Immunotherapy 9 (2), 123-130, 2017 | 102 | 2017 |
| Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma W Qi, LS Cooke, X Liu, L Rimsza, DJ Roe, AMDO Persky, TP Miller, ... Biochemical pharmacology 81 (7), 881-890, 2011 | 101 | 2011 |
| Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies A Forero-Torres, R Ramchandren, A Yacoub, MS Wertheim, WJ Edenfield, ... Blood, The Journal of the American Society of Hematology 133 (16), 1742-1752, 2019 | 99 | 2019 |
| Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma R Schaffel, CV Hedvat, J Teruya-Feldstein, D Persky, J Maragulia, D Lin, ... Annals of Oncology 21 (1), 133-139, 2010 | 97 | 2010 |
| Positron emission tomography–directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of intergroup national clinical trials network study S1001 DO Persky, H Li, DM Stephens, SI Park, NL Bartlett, LJ Swinnen, PM Barr, ... Journal of Clinical Oncology 38 (26), 3003-3011, 2020 | 94 | 2020 |
| Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B‐cell lymphoma KA Cycon, K Mulvaney, LM Rimsza, D Persky, SP Murphy Immunology 140 (2), 259-272, 2013 | 83 | 2013 |
Richard I. FisherPresident & CEO, Fox Chase Cancer Center, Temple University在 fccc.edu 的电子邮件经过验证
